SCHEMBL10107767

SCHEMBL10107767

C=C(C)C(=O)N1CCC(OCc2nc(-c3ccncc3)no2)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.71
LMNA P02545 5/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
TSHR P16473 4/20 0.45
CHRNA7 P36544 1/20 0.43
RAB9A P51151 6/20 0.42
RECQL P46063 2/20 0.42
HPGD P15428 2/20 0.42
ALDH1A1 P00352 2/20 0.42
NPC1 O15118 5/20 0.41
TP53 P04637 1/20 0.41
NFKB1 P19838 1/20 0.41
CASP3 P42574 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
GSTP1 P09211 4/20 0.40
MAPT P10636 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1069801 0.86 GPR119 (0.74) GPR119LMNASMN1; SMN2TSHRCHRNA7
SCHEMBL387143 0.86 GPR119 (0.80) GPR119LMNASMN1; SMN2TSHRCHRNA7
SCHEMBL387294 0.85 GPR119 (0.79) GPR119LMNASMN1; SMN2TSHRCHRNA7
SCHEMBL389587 0.85 GPR119 (0.79) GPR119LMNASMN1; SMN2TSHRCHRNA7
SCHEMBL390532 0.84 GPR119 (0.71) GPR119LMNASMN1; SMN2TSHRCHRNA7
SCHEMBL304401 0.83 GPR119 (1.00) GPR119LMNASMN1; SMN2TSHRCHRNA7
SCHEMBL386716 0.83 GPR119 (0.76) GPR119LMNASMN1; SMN2TSHRCHRNA7
SCHEMBL389342 0.83 GPR119 (0.70) GPR119LMNASMN1; SMN2TSHRCHRNA7
SCHEMBL386190 0.83 GPR119 (0.76) GPR119LMNASMN1; SMN2TSHRCHRNA7
SCHEMBL387115 0.83 GPR119 (0.70) GPR119LMNASMN1; SMN2TSHRCHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207147-B2 Heterocyclic derivatives as GPCR receptor agonists PROSIDION LIMITED (GB) 2012-06-26 US disclosed
US-20090281060-A1 HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281060-A1 HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS GPR119, GCGR, GLP1R GPR119 1/4885LMNA 4276/4885SMN1; SMN2 2801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.